{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:05:25Z","timestamp":1776283525545,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1136\/ijgc-2021-002727","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T22:25:13Z","timestamp":1623795913000},"page":"1175-1178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial)"],"prefix":"10.1016","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct04261465","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Claudia","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Tudisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanda","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6232-0323","authenticated-orcid":false,"given":"Antonella","family":"Pietragalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-335X","authenticated-orcid":false,"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2021-002727_bb0010","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2021-002727_bb0015","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-019-0562-9","article-title":"Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study","volume":"12","author":"Gao","year":"2019","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2021-002727_bb0020","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2021-002727_bb0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","volume":"64","author":"Onda","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2021-002727_bb0030","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1158\/1078-0432.CCR-07-4953","article-title":"Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin","volume":"14","author":"Evers","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2021-002727_bb0035","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of Brca1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ijgc-2021-002727_bb0040","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/annonc\/mdu187","article-title":"Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors","volume":"25","author":"Balma\u00f1a","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2021-002727_bb0045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2021-002727_bb0050","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ijgc-2018-000035","article-title":"Phase Ib with expansion study of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients","volume":"29","author":"Rivkin","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2021-002727_bb0055","doi-asserted-by":"crossref","first-page":"334.e1","DOI":"10.1016\/j.ajog.2017.05.036","article-title":"Brca mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study","volume":"217","author":"Petrillo","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2021-002727_bb0060","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"Brca mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002727_bb0065","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2021-002727_bb0070","doi-asserted-by":"crossref","first-page":"642.e1","DOI":"10.1016\/j.ajog.2008.06.052","article-title":"Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma","volume":"199","author":"Fagotti","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2021-002727_bb0075","doi-asserted-by":"crossref","first-page":"632.e1","DOI":"10.1016\/j.ajog.2014.06.034","article-title":"Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer","volume":"211","author":"Petrillo","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2021-002727_bb0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2021-002727_bb0085","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and Ca 125 agreed by the gynecological cancer intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2021-002727_bb0090","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/COC.0b013e3181af30d3","article-title":"Prediction of chemotherapy response with platinum and taxane in the advanced stage of ovarian and uterine carcinosarcoma: a clinical implication of in vitro drug resistance assay","volume":"33","author":"Matsuo","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002727_bb0095","article-title":"Common Terminology Criteria for Adverse Events (CTCAE).v.5.0 [5x7]","author":"Cancer Therapy Evaluation Program (CTEP)","year":"2017","journal-title":"Cancer ther. Eval. Progr"},{"key":"10.1136\/ijgc-2021-002727_bb0100","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/ijgc-2019-000232","article-title":"Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes","volume":"29","author":"Nero","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2021-002727_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.08.012","article-title":"Fda ovarian cancer clinical trial endpoints workshop: a Society of Gynecologic Oncology white paper","volume":"147","author":"Herzog","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002727_bb0110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/annonc\/mdx011","article-title":"Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: first-line interventions","volume":"28","author":"Karam","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2021-002727_bb0115","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002727_bb0120","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000513","article-title":"Assessment of a chemotherapy response score (CRS) system for tubo-ovarian high-grade serous carcinoma (HGSC)","volume":"38","author":"Ditzel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"10.1136\/ijgc-2021-002727_bb0125","unstructured":"International Collaboration on Cancer Reporting . Response to neoadjuvant therapy. Available: https:\/\/www.rcpa.edu.au\/Library\/Practising-pathology\/ICCR\/docs\/ICCR_Ovary_Response_neoadjuvant [Accessed 25 Mar 2021]."},{"key":"10.1136\/ijgc-2021-002727_bb0130","first-page":"3547","article-title":"Successful analysis of anticancer drug sensitivity by CD-DST using pleural fluid and ascites from patients with advanced ovarian cancer: case reports","volume":"25","author":"Kawaguchi","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1136\/ijgc-2021-002727_bb0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1525-1438.2006.00752.x","article-title":"Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer","volume":"17","author":"Naniwa","year":"2007","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2400447X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2400447X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2021-002727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:38:58Z","timestamp":1753223938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2400447X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1048891X2400447X"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2021-002727","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2021-002727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}